Compugen Ltd. (CGEN)

3.35
NASDAQ : Health Technology
Prev Close 3.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.25 / 5.40
Avg Volume 219.40K
Exchange NASDAQ
Shares Outstanding 51.13M
Market Cap 158.51M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen Presents New Preclinical Data Demonstrating The Distinctive Features Of The PVRIG Pathway In Immuno-Oncology And The Potential Of COM701 For Treating Multiple Solid Tumors

Compugen Presents New Preclinical Data Demonstrating The Distinctive Features Of The PVRIG Pathway In Immuno-Oncology And The Potential Of COM701 For Treating Multiple Solid Tumors

Data Further Strengthens Compugen's Rationale for Clinical Development Planand Biomarker Strategy for COM701

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Compugen To Initiate Manufacturing Of COM902, Its Lead Anti-TIGIT Monoclonal Antibody

Compugen To Initiate Manufacturing Of COM902, Its Lead Anti-TIGIT Monoclonal Antibody

COM902 IND anticipated in 2019 to allow clinical testing of combination therapies with COM701

Compugen To Enter Research Collaboration With Mount Sinai On Novel Myeloid Immuno-Oncology Targets

Compugen To Enter Research Collaboration With Mount Sinai On Novel Myeloid Immuno-Oncology Targets

Multi-year collaboration led by Dr. Miriam Merad

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Compugen To Present At The Annual Meeting Of The Society For Immunotherapy Of Cancer Next Month

Two poster presentations will present new COM701 and COM902 data

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

A New Immunomodulatory Target Discovered By Compugen Demonstrates Potential For First-in-Class Cancer Therapy

A New Immunomodulatory Target Discovered By Compugen Demonstrates Potential For First-in-Class Cancer Therapy

Supportive data generated as part of collaboration with the Johns Hopkins University School of Medicine

Compugen To Present At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

Compugen To Present At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

Presentation will include new data on CGEN-15032, a novel target for cancer immunotherapy

Compugen Welcomes Paul Sekhri As Its New Chairman Of The Board

Compugen Welcomes Paul Sekhri As Its New Chairman Of The Board

Appointment to take effect October 2, 2017

Compugen Discloses Updates To Collaborative Activities With Bayer In Immuno-Oncology

Compugen Discloses Updates To Collaborative Activities With Bayer In Immuno-Oncology

Current Agreement to continue based on CGEN-15001T

Compugen Announces Issuance Of U.S. Patent For COM701, Its Lead Immuno-Oncology Product Candidate

Compugen Announces Issuance Of U.S. Patent For COM701, Its Lead Immuno-Oncology Product Candidate

Patent issued by USPTO under pilot program in support of the White House Cancer Moonshot program

Compugen Presents At ASCO COM701 Drug Combination Data With TIGIT And PD-1 Inhibitors In Preclinical Models

Clinical advisory meeting held in preparation for COM701 clinical studies anticipated to begin next year

Compugen Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen is Now Oversold (CGEN)

Compugen is Now Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Compugen (CGEN)

Oversold Conditions For Compugen (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Compugen

Relative Strength Alert For Compugen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...